We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$53.4B
$31.8M 1.2%
84,021
+7,386
+10% +$2.76M
ISRG icon
27
Intuitive Surgical
ISRG
$127B
$29.9M 1.13%
112,680
+8,277
+8% +$2.02M
JAZZ icon
28
Jazz Pharmaceuticals
JAZZ
$15.9B
$29.1M 1.1%
182,782
– –
DHR icon
29
Danaher
DHR
$137B
$28.1M 1.06%
119,218
-21,281
-15% -$4.93M
IDXX icon
30
Idexx Laboratories
IDXX
$44.1B
$27.8M 1.05%
68,065
+13,858
+26% +$5.38M
MDT icon
31
Medtronic
MDT
$109B
$25.4M 0.96%
326,172
– –
HCA icon
32
HCA Healthcare
HCA
$87.2B
$25.2M 0.95%
105,003
-19,300
-16% -$4.32M
MCK icon
33
McKesson
MCK
$100B
$24.9M 0.94%
66,455
+32,798
+97% +$12.2M
DXCM icon
34
DexCom
DXCM
$32.2B
$24.7M 0.93%
218,015
-27,697
-11% -$3.04M
MOH icon
35
Molina Healthcare
MOH
$10.2B
$24.3M 0.92%
73,615
-45,920
-38% -$15.6M
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$11.6B
$23.9M 0.9%
230,790
+79,843
+53% +$7.5M
ZTS icon
37
Zoetis
ZTS
$32.4B
$20.1M 0.76%
136,914
– –
SRPT icon
38
Sarepta Therapeutics
SRPT
$1.57B
$18.3M 0.69%
140,959
-25,000
-15% -$2.9M
NVO
39
Novo Nordisk
NVO
$208B
$17.7M 0.67%
261,046
– –
LNTH icon
40
Lantheus
LNTH
$6.49B
$17.5M 0.66%
342,872
+113,693
+50% +$7.01M
CRL icon
41
Charles River Laboratories
CRL
$11.2B
$15.8M 0.6%
72,675
– –
BNTX icon
42
BioNTech
BNTX
$22.9B
$15.6M 0.59%
103,858
+8,816
+9% +$1.36M
ASND icon
43
Ascendis Pharma A/S
ASND
$16B
$15.1M 0.57%
123,791
+55,997
+83% +$6.5M
QURE icon
44
uniQure
QURE
$3.03B
$14.8M 0.56%
652,446
+130,753
+25% +$2.82M
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
$14.4M 0.54%
112,214
+58,827
+110% +$7.59M
NBIX icon
46
Neurocrine Biosciences
NBIX
$16.8B
$13.5M 0.51%
112,908
-55,200
-33% -$6.47M
IQV icon
47
IQVIA
IQV
$38.7B
$12.9M 0.49%
63,117
-4,700
-7% -$953K
GH icon
48
Guardant Health
GH
$21.5B
$12.8M 0.49%
472,184
+126,100
+36% +$5.77M
EW icon
49
Edwards Lifesciences
EW
$49.6B
$12.8M 0.48%
171,388
– –
RMD icon
50
ResMed
RMD
$30.6B
$12.6M 0.48%
60,699
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.